Sheldon Sloan, MD

Abivax, France

Poster(s):

• P3533 - Obefazimod in Patients With Moderate-to-Severe Ulcerative Colitis: Efficacy and Safety Analysis from the 96-week Open-label Maintenance Phase 2b Study
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT

• P3534 - Long-Term Upregulation of miR-124 in Blood and Rectal Biopsies of Patients With Moderate-to-severe Ulcerative Colitis Receiving Obefazimod 50mg Daily for 96 weeks
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT

• P3535 - Correlation of miR-124 Upregulation and PK Parameters in Blood of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod for 16 Weeks
  Tuesday, October 24, 2023

  10:30 AM – 4:00 PM PT